Nov. 30, 2023 7:51 am ET
AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company’s entry into the commercial market for ovarian cancer.
AbbVie on Thursday said it will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday’s closing price of $16.06 for the Waltham, Mass., pharmaceutical company.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Source: finance.yahoo.com
Related posts:
Ask an Advisor: What Happens to I Bonds Now That Interest Rates Have Changed?
Time to Pounce: 2 Historically Cheap Ultra-High-Yield Energy Stocks That Are Begging to Be Bought Ri...
Moving to Florida could save Jeff Bezos at least $600 million. How Florida became ‘nirvana’ for the ...
Is it possible to save too much for retirement? The top 3 signs you're going way overboard
Stock market news live updates: Stocks extend losses in downbeat start to September